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Abstract 
The rapid development of nanotechnology provides alternative approaches to overcome several limitations of 
conventional anti-cancer therapy. Drug targeting using functionalized nanoparticles to advance their transport to 
the dedicated site, became a new standard in novel anti-cancer methods. In effect, the employment of nanoparticles 
during design of antineoplastic drugs helps to improve pharmacokinetic properties, with subsequent development of 
high specific, non-toxic and biocompatible anti-cancer agents. However, the physicochemical and biological diversity 
of nanomaterials and a broad spectrum of unique features influencing their biological action requires continuous 
research to assess their activity. Among numerous nanosystems designed to eradicate cancer cells, only a limited 
number of them entered the clinical trials. It is anticipated that progress in development of nanotechnology-based 
anti-cancer materials will provide modern, individualized anti-cancer therapies assuring decrease in morbidity and 
mortality from cancer diseases. In this review we discussed the implication of nanomaterials in design of new drugs 
for effective antineoplastic therapy and describe a variety of mechanisms and challenges for selective tumor tar-
geting. We emphasized the recent advantages in the field of nanotechnology-based strategies to fight cancer and 
discussed their part in effective anti-cancer therapy and successful drug delivery.
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Background
Despite the continuous improvement of cancer fighting 
strategies, malignancies are one of the leading causes 
of death worldwide. Over the last decades a number of 
novel antineoplastic compounds, acting through induc-
tion of apoptosis, dysfunction in cell cycle, gene tran-
scription and inhibition of angiogenesis process, have 
been presented [1]. Nevertheless, the standard anti-
cancer treatment is still based on combined surgical 
intervention, radiation and chemotherapy. The use of 
these methods is limited due to anti-cancer drugs toxic-
ity, their poor selectivity, possibility of cancer recurrence 
and the induction of drug-resistant cancer cells [2]. 
The growing number of studies confirmed that big 
part of these limitations might be overcome using new 
nanotechnology-based tools [2, 3]. A variety of nano-
structures including synthetic biodegradable polymers, 
such as chitosan (CS), polycaprolactone (PCL) or poly-
lactic-co-glycolic acid (PLGA), lipids (liposomes, nano-
niosomes, solid-lipid nanoparticles), mesoporous silica 
nanoparticles (MSNs), micelles, quantum dots (QDs), 
carbon nanotubes (CNTs) and iron oxide magnetic 
nanoparticles (MNPs) have been investigated [4–10]. 
It is recognized, that nanoparticles exhibit the medical 
potential due to a broad spectrum of unique physico-
chemical and biological features including large surface/
volume ratio, specific structural properties, an ability to 
attach some specific agents on their surface, capability to 
cross cell or tissues barriers and long circulation time in 
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blood when compared to other particles. The summary 
of properties determining the employment of nanostruc-
tures in medical application is presented in Fig.  1. It is 
well established that nanoparticles’ small sizes facilitate 
their administration through oral, nasal, parenteral and 
intraocular routes [2]. In addition, their internalization 
via endocytosis, phagocytosis, pinocytosis and macropi-
nocytosis process is possible as well [11]. A number of 
studies confirmed that size, shape, hydrodynamic diam-
eter and properties of nanoparticles’ surface determine 
their residual time in blood, their renal clearance, pro-
tein absorption, toxicity, uptake into mammalian cells 
and in  vivo tumor targeting efficiency [12–18]. Inter-
estingly, the study by Palanki et  al. revealed, that size 
of silver nanoparticles (AgNPs) determines the chemo-
preventive effectiveness of AgNPs against UVB-induced 
DNA damage during apoptosis and influences the pro-
tective effect of these structures against skin cancers 
[19]. It was also demonstrated that surface properties 
of nanomaterials govern physicochemical stability. High 
positive or negative zeta potential is associated with 
their stability preventing accumulation of stored mate-
rials. Moreover, recent study conducted by Yang et  al. 
confirmed that positively charged gold nanoparticles 
(AuNPs) are better internalized by breast cancer cells 
than particles with negative charge [20]. The character of 
surface charge represents an important parameter deter-
mining biological activity of nanomaterials [21–23]. The 
size of MNPs’ core influences also magnetic properties 
of these structures which are crucial for their employ-
ment in magnetic fluid hyperthermia (MFH), magnetic 
resonance imaging (MRI) and magnetic-mediated tar-
geted delivery [24]. Simultaneously, amphipathic proper-
ties of lipid-based nanostructures, such as liposomes or 
micelles, controls the payload drugs accumulation into 
tumor tissues and are suitable to deliver drugs character-
ized by low solubility in water environment and agents 
of various chemical nature [25, 26].
Unique nanomaterials properties makes possible to 
employ nanostructures in a number of biological appli-
cations, such as drug delivery systems (DDS), contrast 
agents for MRI or computer tomography (CT) imag-
ing and as diagnostic tools for high-specific detection 
of macromolecules and pathogens [3, 27–29]. In this 
review, we summarize the potential of nanotechnol-
ogy in modern therapy of cancer diseases and high-
light the recent advantages in this field. In addition, we 
discussed the studies using nanomaterials suitable for 
medical application and described a variety of mecha-
nisms allowing their employment as nanostructures 
Fig. 1 Physicochemical features of different nanomaterials proposed as drug carriers in drug delivery systems and targeted therapy. The most 
important properties of nanomaterials determining their theranostic potential, employment in medical applications and effect on pharmacokinetic 
parameters in vivo conditions, including biodistribution, toxicity and internalization into target cells
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to overcome some limitations of conventional anti-
cancer methods. Firstly, we present data confirming 
the possibility of nanotechnology application in order 
to improve selectivity of antineoplastic compounds via 
passive and active drug delivery strategy, using mono-
clonal antibodies, aptamers, nucleic acid, peptides and 
stimuli-responsive nanocarriers. Next, we discuss the 
nanotechnology-based approaches to overcome the 
chemotherapeutics resistance by preventing drugs 
efflux and enhancing the intracellular uptake, modulat-
ing ceramide levels and targeting MDR-associated genes 
and proteins. Furthermore, we highlighted the recent 
advantages in design of antineoplastic strategies in order 
to improve pharmacokinetic parameters of anti-cancer 
drugs, increasing their low water-solubility, optimization 
of its controlled release and upgrading of oral bioavail-
ability and chemical stability. We also discussed how 
physical properties of nanomaterials might contribute 
to intensification of standard anti-cancer procedures. 
With respect to considerable achievements in nano-
technology-based strategies, we bring a brief summary 
of limitations facing nanotechnology-based therapies 
and governing pre-clinical studies and summarized the 
results of newest clinical trials after their translation in 
clinical settings.
Nanomaterials‑based targeted drug 
delivery systems to increase low selectivity 
of chemotherapeutics
Therapeutic agents’ delivery to the target site is a major 
challenge in the treatment of a variety of diseases, 
including cancer, and the development of nanoparti-
cle-based anti-cancer drugs and gene delivery systems 
denotes a favorable approach. Chemotherapeutics, 
currently used in the treatment of solid tumors and 
hematological malignancies, are systemically distrib-
uted without preferential localization to the tumor tis-
sue, which results in high toxicity against healthily cells 
[2]. The employment of nanostructures as drug nano-
carriers provides an effective way to minimize the side 
effects and to improve pharmacological properties of 
conventional antineoplastic agents. As the platforms 
for drug delivery systems liposomes, solid lipids nano-
particles, dendrimers, silicon nanostructures, polymer 
conjugates, micelles, carbon nanomaterials and protein 
or nucleic acid-based nanoparticles have been tested 
[30–34]. However, despite a variety of nanomaterials 
designed for cancer targeting, only a limited number of 
liposomes and polymer nanoformulations were clini-
cally approved. Several drug-targeting strategies can be 
engaged to reach target tissue. Those include passive and 
active drug targeting and magnetic field-mediated and 
triggered drug delivery.
Passive drug targeting strategy
The passive targeting strategy rest on preferential drug 
accumulation in tumor cells achieving trough enhanced 
vascular permeability and retention effect (EPR). The 
concept of this phenomena and its impact on transport 
of nano-drugs into cancer tissues was formulated for the 
first time in 1986 [35]. This theory is based on the fact, 
that tumor vasculature is characterized by discontinuous 
epithelium, impaired lymphatic drainage and reduced 
uptake of the interstitial fluid in contrast to normal blood 
vessels with firmly sealed endothelium. Subsequent 
accumulation of macromolecules provides the environ-
ment supporting the passive transport of nanotherapeu-
tics to the target site [36]. High heterogeneity of EPR 
effect cause a significant limitation of this strategy, not 
only among different patients, but also in the case of the 
same subject, which whom a varied distribution of pore 
sizes and consequently, diverse drug delivery might be 
observed [37]. A precise impact of EPR effect on nano-
particles accumulation in tumor tissues is also difficult 
to determine, since a variety of nanoparticle properties, 
including shape, size, zeta potential, presence of hom-
ing ligands is involved in this process [38]. Previously, 
some drug delivery systems using this strategy were 
introduced to clinical trials. Such agent was SP1049C—
pluronic polymeric micelle-based nanoparticles caring 
doxorubicin tested for advanced adenocarcinoma of the 
esophagus and gastroesophageal junction treatment and 
murine leukemia. It was reported that SP1049C decline 
tumorigenicity and aggressiveness of cancer in  vivo 
and diminishes BCRP (breast cancer resistant protein) 
overexpression. It also modifies DNA methylation pro-
files, which results in sensitization of MDR cancer cells 
to antineoplastic treatment [39, 40]. In 2005 and 2008, 
SP1049C has received an orphan drug designation from 
FDA for the treatment of esophageal carcinoma and gas-
trointestinal cancer, respectively. Other nanoformulation, 
tested in clinical trials, was NK911—micelle encapsulated 
doxorubicin proposed for the treatment of various solid 
tumors. However, to date no development news related 
to SP1049C and NK911 has been reported and trials are 
not listed in database provided by U.S. National Institutes 
of Health [41]. Passive drug strategy appears to contrib-
ute as well in in  vivo tumor targeting of the bile acid-
conjugated chondroitin sulfate A-based nanoparticles 
(CSA-DOCA NPs) presented recently for the delivery of 
doxorubicin by Lee et al. [42]. A significant restriction in 
passive drug strategy is small and insufficient accumu-
lation of drugs in target cancer tissues. It was reported, 
that transport of anti-cancer agents via EPR effect results 
in internalization into cancer cells only a small part of the 
injected dose [43]. In response to this limitation, active 
drug targeting strategy has been developed (Fig. 2).
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Active drug delivery strategy
Presence of specific homing ligands, attached on the 
surface of nanosystem and enabling active binding with 
receptors overexpressed on tumor cells represent a 
standard model of active drug delivery strategy. A num-
ber of molecules, including transferrin-receptors (TfR), 
epidermal growth factor receptors (EGFR), folate recep-
tors (FR), CD44 or CD22 can be engaged in this manner 
[34, 44–47]. Accordingly, tumor-specific ligands interact 
with receptors on the surface of cancer tissues, trigger-
ing receptor-mediated endocytosis and internalization 
of nanoparticle into cancer cells [48]. Surface of nano-
therapeutics can be functionalized by a number of tumor 
targeting agents including small molecules, peptides, 
monoclonal antibodies (mAb) or their fragments, aptam-
ers and nucleic acids.
Monoclonal antibodies
For several years the most promising class of hom-
ing ligands used in the design of targeted nanoparti-
cles were monoclonal antibodies. They are successful in 
several antibodies-based anti-cancer therapeutics act-
ing through induction of antibody-dependent cellular 
cytotoxicity (ADCC) and complement dependent cyto-
toxicity (CDC) [49]. According to studies performed 
by Kirpotin et  al. the engagement of immunoliposomes 
significantly improves intracellular uptake of nano-drug, 
without considerable effect on tumor localization [50]. 
Fig. 2 Active drug delivery using targeted ligand/moieties and stimuli-responsive nanoformulations. Figure presents the model of diblock co-
polymer nanoparticles with protective cover around the core and stimuli-response shell. Passively circulated nanoparticles accumulate in tumors 
via enhanced permeability and retention (EPR) effect and are released into extracellular environment of tumor. The attachment of homing ligands, 
targeted against specific moieties on the surface of cancer cells makes available for recognition of tumor cells from normal cells. Additionally, the 
specificity of nanoparticles-based therapeutics might be enhanced due to employment of nanosystems sensitive to triggering by external factors, 
such as temperature, light, and magnetic field, alternations in pH value or as effect of biological activity of enzymes, which allows for release of 
factors-activated payload drugs into cancer cells via receptor-mediated endocytosis, phagocytosis, pinocytosis or macropinocytosis
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In such manner rituximab—an IgG1 antibody binding 
to the CD20 receptor, present on the cells of most B cell 
neoplasms, were tested as an example of mAb immobi-
lized on the surface of nanomaterials [51, 52]. Studies 
performed by Popov et  al. demonstrated that PLA-con-
jugated rituximab show a significant improvement in the 
cellular uptake and ADCCC/CDC effect when compared 
to non-targeted counterparts [53]. However, a number 
of limitations and restrictions governing the develop-
ment of mAb-based nanotherapeutics, including high 
synthesis costs, large size, immunogenic properties, rapid 
nanoparticle clearance and sensitivity to environmental 
encounters, such as temperature, salt concentration and 
enzyme with subsequent poor resistance to organic sol-
vents results in limited number of full antibody targeted 
nanoparticle in clinical testing [54]. In currently ongoing 
clinical trials antibodies’ fragments in liposome-based 
nanoformulations, such as C225-ILS-DOX or SGT-53, 
were reported. Importantly, Fab fragments make avail-
able to preserve high antigen binding specificity follow-
ing by smaller size of synthetized nanoformulations and 
less immunogenicity [36]. Recently, Ahmed et  al. dem-
onstrated the results suggesting that immobilization of 
antibodies onto a surface of gold-coated nanoparticles 
significantly decreases the ability of cetuximab to initi-
ate an ADCC response in EGFR-expressing H1975 tumor 
xenografts [55]. In contrast, cetuximab and its fragment 
were employed in synthesis of oxaliplatin-loaded EGFR-
targeted liposomes tested for treatment of EGFR-positive 
colon cancer. Co-treatment with receptor-targeted anti-
bodies and liposomes as drug delivery nanoformulations 
results in increased cytotoxic activity against cancer cells. 
Additionally, the employment of Fab’ fragments enable 
to eliminate the uptake by phagocytic cells resulting in 
better biocompatibility and in vivo efficacy [56]. Further-
more, Fan et  al. provided a novel AuNPs-conjugated-
rituximab-based immunodetection method to label and 
image specifically the CD20 on the malignant lymphoma 
Raji cells surface [52]. Sun et  al. proved that dimercap-
tosuccinic acid-modified iron oxide MNPs co-loaded 
with anti-CD22 antibodies and doxorubicin (anti-CD22-
MNPs-DOX) may be employed as drug nanocarriers 
in the treatment of non-Hodgkin’s lymphoma due to 
increased uptake of DOX and induction of apoptosis pro-
cess [46].
Aptamers
The second class of tumor targeting ligands are aptamers, 
defined as short single-stranded RNA or DNA sequences 
of oligonucleotides capable to interact with target recep-
tors on the surface of cancer tissues with the selectivity 
and affinity compared with those observed for mono-
clonal antibodies. With respect to the unique properties 
of monoclonal antibodies, small size of aptamers, their 
decreased immunogenicity and associated with it bet-
ter biodistribution and stability encourage to the devel-
opment of aptamers-based nanoformulations suitable 
for medical application [57]. Immobilization of cancer 
cell-specific single-strand DNA aptamers on the nano-
structures may provide an effective strategy to develop 
new drug delivery systems. It was demonstrated that 
the employment of DNA aptamers with doxorubicin-
encapsulated DOTAP/DOPE nanoparticles in the treat-
ment of breast cancer significantly suppress the tumor 
growth and increased the animal survival rate in xeno-
grafts model [58]. Moreover, nanoformulations pre-
sented by Roy et al. based on Fe3O4-saturated lactoferrin 
(Fe3O4-bLf) nanocarriers with locked nucleic acid (LNA) 
modified aptamers, improve the survival rate in the tri-
ple positive xenograft colon cancer model (EpCAM, 
CD133, CD44), due to phosphorylation of p53, induction 
of apoptosis and mitochondrial depolarization. In this 
setting a complete regression of tumor was observed in 
70 % of mice. In addition to anti-cancer properties, it is 
hypothesized that these multi-functional nanosystems 
may be employed in near-infrared (NIR), MRI and CT 
imaging [59]. Some reports supporting the anti-cancer 
potential of aptamers and their utility in the active drug 
targeting strategy are presented in Table 1.
Targeting ligands based on peptides, proteins and small 
molecules
Recently, TfR, involved in the transport of iron, necessary 
for cell proliferation, through the biological membrane 
became a biological target for transferrin-based drug 
nanocarriers. TfR are overexpressed in a variety of malig-
nancies (up to 100-fold higher than the average expres-
sion in normal cells) and due to their ability to internalize 
into cells in a clathrin/dynamin-dependent manner and 
their recycling back to the cell surface, they might be 
employed in DDS. Importantly, targeting of TfRs can be 
facilitated through the use of variety drug delivery strate-
gies, including these using transferrin, specific peptides, 
mAb or single chain antibody fragments specific for the 
extracellular domain of these receptors [60]. Transferrin-
decorated PEGylated AuNPs accumulate specifically in 
cancer cells, in contrast to healthily liver tissues, which 
was investigated using Neuro2A cells-bearing mice. It 
was confirmed that employment of specific ligand that 
promote the incorporation of nanotherapeutics into neo-
plastic cells via receptor-mediated endocytosis results 
in optimized release of the drug, promoting a better 
therapeutic action, while limiting non-specific trans-
port of nanocarriers to the healthy cells of the patients 
takes place [61]. Moreover, nanocomposite consisting of 
transferrin-functionalized AuNPs and graphene oxide 
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(Tf-AuNPs/GO) was developed as NIR-based fluores-
cent probe for bioimaging cancer cells [62]. Eradication 
of breast cancer MDA-MB-231 cells was successful with 
transferrin-receptor engaged as target molecule for vita-
min E TPGS (d-alpha-tocopheryl polyethylene glycol 
1000 succinate)-based nanosystems encapsulated in the 
lipophilic core of the micelles [34]. Studies performed 
on mice brain cancer model revealed that PLGA poly-
meric nanocarriers might be employed for delivery of 
transferrin-methotrexate conjugates. Jain et  al. demon-
strated that development of transferrin-based nanosys-
tems improved biocompatibility and greater anti-tumor 
activity against brain cancer [33]. Nanoformulation using 
TPGS might also be employed in treatment of doxo-
rubicin-resistant breast cancer and in co-treatment of 
multidrug resistance tumors with paclitaxel and 5-fluo-
rouracil [4, 63]. Overexpressed in a number of malignan-
cies folate-receptors (FR) represent another promising 
target moiety for anti-cancer treatment. Folic acid, due to 
its high affinity to these receptors has been used in DDS 
designed for the treatment of breast cancer, as element of 
photodynamic therapy, when conjugated with multifunc-
tional cobalt ferrite nanoparticles or as targeted CT con-
trast agents in perfluorooctylbromide nanoformulations 
(FR-TPNPs) for early diagnosis of ovarian cancer [25, 47, 
64, 65]. The current interest of scientists focuses also on 
tumor-homing peptide—CREKA (Cys-Arg-Glu-Lys-Ala), 
recognizing fibrin-associated plasma proteins, overex-
pressed on cancer cell surface. Due to leaky vasculature 
of tumors and the presence of fibrin-fibronectin com-
plexes within antineoplastic tissues, CREKA possess the 
ability to specifically target cancer cells and internalizing 
into their cytoplasm. The special feature of this pentapep-
tide includes stimulation of platelet clot formation within 
tumors tissues, which increase the uptake of CREKA-
conjugated nanoparticles. Furthermore, nanoparticles 
localized in tumor cells induce additional local clotting, 
which results in amplified influx of further amounts of 
particles [66]. CREKA-based nanoformulations are cur-
rently investigated in terms of their use in the treatment 
of non-small cell lung cancer and breast cancer [67, 68].
An ever-growing number of studies confirmed that 
peptides belonging to the family of natural antimicrobial 
peptides (AMPs) might be employed in targeted anti-
cancer therapy. It was demonstrated that LL-37 peptide 
proteolytically released from human cathelicidin protein 
(hCAP18) and its synthetic analogs (i.e. ceragenins) are 
characterized by a broad spectrum of pleiotropic activ-
ity, including their influence on carcinogenesis [69–72]. 
Previous studies established that anti-cancer potential 
of AMPs is determined by high membrane activity of 
these compounds resulting in alternation of biological 
membrane architecture and increased permeability. A 
hCAP18 based nanosystems can be used in the combina-
tion anti-cancer therapy of ovarian cancers [73]. Impor-
tantly, positively charged AMPs and its analogs possess 
high affinity to cancer tissues having a negative surface 
charge, which provides a way to distinguish neoplastic 
from normal cells. Our previous studies revealed, that 
LL-37-induced apoptosis of colon cancer DLD-1 cells can 
be enhanced using MNPs as drug nanocarriers [74]. The 
use of nanoparticles allows to design of high biocompat-
ible ceragenins-based nanosystems, since immobilization 
of CSA-13 on the surface of MNPs decrease the hemo-
lytic activity of ceragenin, observed in the case of non-
conjugated compounds [75]. Data presented by Kuroda 
et  al. indicates that these nanoformulations give great 
hope for effective colon cancer therapy [76, 77]. Clinically 
significant tumor ligands conjugated in nanoparticles 
systems are summarized in Table 2.
Employment of nanomaterials for delivery 
of nucleic acid‑based drugs
The miRNAs play a crucial role in cancer develop-
ment and might be used as therapeutic targets for novel 
antineoplastic agents. Recent research confirmed that 
miRNAs promote cancer invasion and migration, are 
involved in acquired chemoresistance and are consid-
ered as a predictive factor for chemotherapy response 
and a prognostic factor for overall survival in a variety 
of malignancies [78–80]. Since antisense oligonucleo-
tides (ASOs or anti-RNAs) bind directly to miRNAs and 
Table 1 The engagement of aptamer‑based nanoformulations in anti‑cancer therapy
Type Nanoformulation Indication Reference
Anti-HER2 aptamer (HApt) Gold nanoparticles HER-2 positive breast cancer [207]
CD133 aptamer Salinomycin-loaded PEGylated PLGA nanoparticles Osteosarcoma [208]
CD133 aptamers A15 and EGFR aptamers CL4 Salinomycin-loaded PLGA nanoparticles Hepatocellular carcinoma [209]
EGFR-targeting aptamers Triple-functional pRNA-3WJ nanoparticles Triple-negative breast cancer [210]
EpCAM aptamer Doxorubicin-loaded PEG-PLGA nanoparticles Non-small cell lung cancer [211]
Mucin 1 aptamer Gold nanoparticle-hybridized graphene oxide Breast cancer [212]
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block their biological activity, they possess the potential 
to be employed for anti-cancer therapy. One of ASOs is 
an anti-miR-150 expression vector (PR-ASO-150) con-
structed to inhibit proliferation of lung adenocarcinoma 
A549 cell line by regulating of expression of miRNA-150 
[81]. In 2015 Tao et  al. demonstrated that use of vec-
tor encoding ASOs against miR-21 (p-miR-21-ASO) 
impairs the invasion and proliferation ability of colon 
cancer cells. This effect was achieved due to reversed 
PTEN (phosphatase and tensin homolog) expression and 
altered the transduction of AKT and ERK pathways in 
cancer cells [82]. Since both of these factors is involved 
in tumorigenesis (PTEN is recognized as tumor suppres-
sor and angiogenesis inhibitor and AKT/ERK pathway 
is associated with cancer progression) it was concluded 
that the employment of anti-mRNA factors might be use-
ful for development of biological anti-cancer therapies 
[83]. Nevertheless, a significant limitation in ASOs-based 
therapy is low intratumor internalization conditioned 
by large molecular weight and high surface charge of 
ASOs, their poor stability and adverse effects induced 
by systemically administered anti-RNAs [84]. In order to 
solve these problems, a number of researchers focus on 
design of antisense oligonucleotides-loaded nanoparti-
cles. Previously, it was presented that loading of human 
serum albumin nanoparticles with trastuzumab-modified 
ASOs increase their pharmacokinetic properties with-
out affecting their impact on gene expression [85]. Costa 
et  al. designed chlorotoxin-based nanoparticles coupled 
to liposomes encapsulating anti-RNAs for the mod-
ern therapy of glioma. A common mechanism of action 
involving the binding of chlorotoxin selectively to glioma 
cells (and not to health cells) and nanosystem-mediated 
silencing of miR-21 resulted in overexpression of PTEN 
and PDCD4 (programmed cell death protein 4; tumor 
suppressor) activation of caspase 3/7-dependent apop-
tosis and impaired cell proliferation [86]. Additionally, 
study conducted on mice model presented that nanopar-
ticles-mediated delivery of ataxia-telangiectasia-mutated 
(ATM; radiosensitization gene) ASOs provide a way to 
sensitize of head and neck squamous-cell carcinoma 
cells to irradiation [87]. The newest studies presented by 
Li et al. confirmed great potential of these agents in the 
treatment of acute myelogenous leukemia [88]. However, 
a better understanding of uptake mechanism of ASOs is 
crucial for development of anti-RNAs as effective anti-
neoplatic compounds. Recently, Ezzat and colleagues 
confirmed that mechanism of cellular uptake of some 
ASOs is dependent on their self-assembly into nanopar-
ticles, forming micelles, obtaining negative charge and 
involves binding to class A scavenger receptor subtypes 
(SCARAs) [84].
Table 2 Examples of target moieties in anti‑cancer nanoformulations
Target moiety Nanoformulation Active compound Indication Therapy Reference
Epidermal growth factor 
receptor
Peptide-targeted gold  
nanoparticles
Pc 4 Brain cancer Photodynamic therapy [213]
Epidermal growth factor 
receptor







coated iron oxide  
nanoparticles





Doxorubicin Breast cancer Chemotherapy [68]
Folate receptors PLGA polymeric  
nanoparticles
Doxorubicin Breast cancer Chemotherapy [47]
Folate receptors Cobalt ferrite nanoparticles Hematoporphyrin Several types of FR-positive 
tumors
Photodynamic therapy [65]
Folate receptors Deoxycholic acid-O-car-
boxymethylated chitosan 
nanoparticles
Paclitaxel Breast cancer Chemotherapy [25]
IL-13Rɑ2 Liposomes Doxorubicin Glioblastoma multiforme Chemotherapy [215]
Integrin receptors RGD-modified liposomes Paclitaxel Hepatocellular carcinoma Chemotherapy [216]
LHRH receptor Gold nanorods Goserelin Prostate cancer Radiotherapy [217]
Transferrin receptors PEGylated gold nanoparticles AuNPs Mouse neuroblastoma Chemotherapy [61]
Transferrin receptors VitE TPGS-encapsulated 
micelles
Docetaxel Breast cancer Chemotherapy [34]
Transferrin receptors PLGA polymeric  
nanoparticles
Methotrexate Brain cancer Chemotherapy [33]
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The development of nanotechnology enabled as well the 
introduction of a number of siRNAs-based anti-cancer 
nanoformulations. Previously, some attempts to make the 
complexes of siRNAs (small interfering RNAs) with cati-
onic lipids and polymers in order to achieve high affinity 
for siRNAs, proper deliver and controlled release into the 
cells and to protect siRNAs from degradation in in  vivo 
conditions were persuaded. However, a significant aggre-
gation of complexes caring positive charge in the presence 
of plasma proteins was followed by rapid elimination by 
phagocytic cells. Such effect might limit their use [89]. 
Presently, nanolipid-based formulations for siRNAs trans-
port are more desirable. Interesting nanoformulation 
using siRNA was introduced by Shah et  al. The multi-
functional nanosystem based on siRNA targeted to CD44 
mRNA and a synthetic analog of luteinizing hormone-
releasing hormone (LHRH) peptide as a tumor-targeting 
moiety to transport paclitaxel conjugated on dendrimer-
based nanoformulation seems very promising. Effective 
delivery of CD44 mRNA-targeting siRNA provides new 
solution to treat metastatic ovarian cancer [45].
The development of gene delivery strategies applica-
ble in the treatment of malignancies results in design of 
nanocarriers for short hairpin RNA (shRNA) molecules 
in order to silence cancer-relevant genes. A consider-
able limitation in delivery of RNA interference factors is 
passive entry of naked shRNA into cells, unsatisfactory 
release of RNAi factors from carriers and escape from 
endosome [90]. To solve this problem, novel nanocarri-
ers, safer than previously tested retroviral-based vectors, 
are needed. Lately, a number of interesting nanopar-
ticle-based formulation for shRNA delivery have been 
presented. Reported combinations were tested against 
hepatocellular carcinoma, glioma, melanoma, ovarian 
and prostate cancers [91–95]. The brief summary of these 
reports is provided in the Table 3.
Triggered drug delivery by stimuli‑sensitive 
nanoparticles
One of the active drug delivery strategies involves 
employment of stimuli-sensitive nanomaterials, releas-
ing the drug in the precise target tissue due to activation 
by external factors or by changes in local endogenous 
conditions. In this strategy, during the first stage, drug 
is passively delivered and accumulated in tumor tis-
sues via the EPR effect. When nanosystem reaches the 
target site, the nanoparticles are activated and release 
incorporated drugs [96]. The ever-growing number of 
studies confirmed that this strategy might lead to the 
development of new class of drug delivery systems [97]. 
To date, a number of stimulus factors, including light, 
radiofrequency (RF) energy, magnetic field, enzymes or 
alternation in pH value, have been explored [9, 31, 98–
101]. Recently, Yingyuad et al. described new PEGylated 
siRNA-nanoparticles activated by human leukocyte 
elastase (HLE) or matrix metalloproteinase-2 (MMP-
2), both present in the extracellular spaces of tumor in 
order to promote invasion and metastasis of cancerous 
cells via degradation of basement membrane and extra-
cellular matrix barrier. The biological activity of enzymes 
results in cleavage of enzyme-responsive linkers and 
release of payload drugs to the target site. Studies per-
formed both with breast cancer MCF-7 cells (HLE pro-
tein-positive) and primate fibroblastoma HT1080 cells 
(expressing MMP-2) confirmed that this formulation 
possess the potential for specific DDS due to controlled 
siRNA release. However, the exact activation mechanism 
is still unclear [102]. MMP-2 proteolytic activity was also 
used in polymer-coated mesoporous silica nanoparticles 
[103], in polystyrene-based nanosystems and PEGylated 
AuNPs conjugated with gelatin as the moiety to activate 
release of doxorubicin [101, 104]. Additionally, van Rijt 
et  al. synthetized avidin-capped MSNs functionalized 
Table 3 Possible shRNA nanocarriers for the treatment of malignancies
SATB1 special AT-rich sequence-binding protein-1, PLGA poly D, L-Lactide-co-glycolide acid, PEI polyethyleneimine, PEG polyethylene glycol, TREM-1 triggering 
receptor expressed on myeloid cells-1, EZH2 the enhancer of zeste homolog 2, CXCR4 CXC motif chemokine receptor 4
Nanoformulation Tested cancer cell lines Results of the study Reference
Hydroxyapatite nanoparticles-delivered plasmid-
based SATB1 shRNA
Human glioma U251 cells Significant inhibition of growth, invasion and 
angiogenesis, down-regulation of SATB1, 
cyclin D1, MMP-2 and VEGF, increased Bax and 
caspase-9 activity
[92]
CD44-targeted shRNA delivered by PLGA-based 
NPs
Human ovarian SKOV-3 cells Inhibition of angiogenesis, proliferation of cells 
and the induction of apoptosis
[45]
PEI-coated gold NPs with chitosan-aconitic anhy-
dride and shRNA
Human hepatocellular carcinoma Enhancement of sensitivity of cancer cells to 
doxorubicin, induction of tumor growth, 
decrease of ABCG2 expression
[91]
PEG-PEI co-polymer/shRNA Prostate cancer Effective inhibition of EZH2 expression [94]
jetPEI-based NPs with CXCR4 shRNA Melanoma Decreased expression of CXCR4 mRNA, inhibition 
of pulmonary metastasis of melanoma cells
[95]
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with linkers, exclusively cleaved by MMP9 for controlled 
release of cisplatin into lung tumors [105]. Lately, sci-
entific interest has focused on the pH-activated nano-
systems. A variety of pH-responding polymers, both 
un- and biodegradable, has been identified [106]. The 
employment of pH-sensitive nanocarriers is based on 
the cancer tissues low pH (pH  ~  6.5), especially their 
endosomes and lysosomes (pH 5.0–5.5) are more acidic 
when compared to blood physiological pH (pH  ~  7.4) 
[107]. Indeed, acidic conditions are required for pro-
tonation of the carboxyl group of laurate followed by 
decrease of the electrostatic interaction between the acid 
and doxorubicin, which results in release of drug from 
SLNs-based nanoformulations. Such were designed for 
treatment of DOX-resistant breast cancers. Importantly, 
the solubility of DOX increased in acidic environment, 
which improves the release rate of drug [31]. Moreover, 
mild acidic conditions, characteristic for tumor environ-
ment facilitate release of DOX from polymer-conjugated 
MSNs due to hydrolysis of the acid-sensitive acetal link-
age and dissociation of polymer coating layer, protect-
ing payload drug from release in physiological pH [108]. 
Recently Wei et  al. presented pH-mediated release of 
DOX from anti-MDR-cancer nanosystems. Nanoformu-
lation based on self-assembling amphiphilic dendrimer 
(AmDM) generates nanomicelles to encapsulate doxoru-
bicin. Studies performed on DOX-resistant breast cancer 
MCF-7 cell line demonstrated that synthetized nanosys-
tem exerts increased anti-proliferation effect due to rapid 
and effective, acidic pH-mediated cellular uptake. It was 
confirmed that terminal primary amines and the ter-
tiary amines in the interior of the dendron become pro-
tonated, giving the dendrimer high positive charge and 
leading to improved drug release. Importantly, AmDM-
based nanoparticles for effective treatment of MDR can-
cers required macropinocytosis process that can bypass 
the efflux pumps contributing to the sufficient uptake of 
antineoplastic agents in MDR tumors [109]. However, 
unspecific partial release of drugs in extracellular envi-
ronment of normal cells, which results in toxic effect in 
place different than target cancerous tissues represents a 
significant limitation of this method [106]. Considering 
those restrictions Huang et al. designed the dual-sensitive 
nanosystem responding not only to alternation in pH, but 
also to cytoplasmic concentration of glutathione (GSH). 
Since it was confirmed that intracellular and extracellu-
lar tumor environments are characterized by the differ-
ent concentrations of GSH (range 1–11 mM and ~10 µM, 
respectively), pH/GSH—co-triggered nanosystem may 
provide a new non-toxic, highly biocompatible system for 
doxorubicin delivery. In effect nanostructure was better 
triggered at pH 5 and 10 mM GSH concentration than in 
the presence of only one factor. Moreover, it was assessed 
that DOX internalized into HeLa cells through endocyto-
sis process followed by drug translocation into the cells’ 
nuclei [110]. The appropriate concentration of GSH is 
also a stimulus factor for camptothecin-loaded nanopar-
ticles [111].
Light as factor activating release of payload drugs from 
stimuli-responsive nanoformulations was presented in 
few previous studies. Nevertheless, the suitable way to 
accomplish drug release in physiological conditions using 
remote light activation and to achieve proper specificity 
to cancer cells is still a challenge. In 2014, Ju et al. dem-
onstrated light-responsive nanosystem developed for 
controlled release of DOX using light-induced pH-jump 
activation and cleavage of the boronic ester linkages. This 
nanosystem is based on photoacid generator (PAG) pro-
ducing strong acid due to illumination with UV or NIR 
light. Immobilization of PAG into graphene oxide-capped 
mesoporous silica in the presence of folic acid-modified 
DOX exhibited selective internalization into cancer cells 
without adverse effects [112]. Release of DOX from NIR 
light-absorbing AuNPs coating with thermally respon-
sive poly-(N-isopropylacrylamide-co-acrylamide) hydro-
gel occurs in similar way [113]. Since polymeric material 
used in such nanosystem is characterized by a temper-
ature-dependent alternated content of water, release 
of load occurs during removal of water from hydrogel 
surface as result of phase transition. Importantly, func-
tionalization of AuNPs with biocompatible polymeric 
surface prevents aggregation of nanotherapeutics in 
physiological conditions, comparable to PEGylated nano-
formulations. Interestingly, Oliveira et  al. used doxoru-
bicin-loaded superparaMNPs to ensure release of DOX 
upon application of a local high frequency magnetic field. 
In this system induced magnetic hyperthermia increased 
cytotoxicity of nanoparticles against HeLa cells [100]. 
Alternating magnetic field (AMF) mediated generation 
of heat by nanocubes provides the way to release DOX 
from thermo-responsive polymer-incorporated iron 
oxide nanocubes due to physical transition of polymer 
in the presence of increased local temperature [114]. 
This is consistent with recent study, demonstrating the 
release of embedded cargo as response to AMF-triggered 
destruction of polymer walls. Considering the limita-
tions for in vivo application of light-induced delivery sys-
tems, particularly the strong absorption of light by tissues 
and restricted penetration depth of light other methods 
should be considered as more suitable for future clini-
cal use. Compared to light, AMFs can penetrate deeper 
into cancer tissues, and it might be employed for deeper 
tumors treatment [115]. The generation of heat in order 
to release incorporated anti-cancer agents was used in 
radiofrequency-triggered drug release, presented as 
novel approach to assure targeted drug delivery. Recently, 
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Du et  al. demonstrated multi-functional nanosystem, in 
which conversion of radiofrequency energy into ther-
mal energy has permitted the release of docetaxel from 
thermosensitive liposomes [116]. Additionally, the use 
of non-invasive RF-field results in disruption of pluronic 
F-108 in pluronic-coated ultra-short nanotubes (USNTs), 
which allows the release of cisplatin from nanoformula-
tion [99]. Other stimuli-sensitive nanoformulations dem-
onstrated in 2015 are summarized in the Table 4.
Nanoparticles‑based approaches to reverse 
multidrug resistance of cancer cells
The numerous mechanisms were reported as involved 
in induction of multidrug resistance (MDR) in different 
cancer cells. Overexpression of ATP-dependent efflux 
pumps, mainly glycoprotein P (P-gp), breast cancer 
resistant protein (BCRP), multidrug resistance associated 
protein (MRP), decreased drug uptake via activation of 
surface transporters, alternations in apoptotic pathway, 
increased capacity to drug-induced DNA repair and acti-
vation of detoxification systems resulting in augmented 
drug elimination should be consider as a mechanism 
leading to MDR [117]. Among them, efflux pumps-medi-
ated resistance is most clinically significant, given into 
account the number of studies reporting drug-induced 
overexpression of MDR proteins as result of chemother-
apy-based treatment and emerging of inflammation in 
the cancerous tissues [118, 119]. Importantly, over 50 % 
of presently used cytotoxic drugs are transported through 
cell membrane using these proteins, which significantly 
hampers the conduction of effective systemic chemother-
apy [120–123]. It is hypothesized that nanotechnology 
provides the way to overcome ATP-proteins-induced 
drug resistance due to employment of nanoparticles as 
drug delivery systems, ensuring sufficiently high concen-
tration of drug in intracellular environment that permit 
to omit the cancer cell resistance [124]. The potential of 
nanoparticles as modern nanocarriers have been pre-
sented in previous sections (see: Targeted drug delivery 
using nanomaterials as the method to overcome lack of 
selectivity of conventional chemotherapeutics). Novel 
nanotechnology-based approaches toward treatment of 
MDR cancers assume the engagement of nanoparticles in 
order to increase intracellular drug accumulation, silence 
of efflux transporters genes and inhibit MDR-associated 
proteins and factors.
Enhancement of intracellular drug retention
One of the most benefited method for reducing tumors 
resistance was developed with increased of the intracel-
lular concentration of anti-cancer drugs that improved 
their therapeutic efficiency. A doxorubicin-containing 
nanoparticles synthetized using folate-terminated poly-
rotaxanes (as a drug carrier) and dequalinium (as a com-
pound for selective delivery of drug into mitochondria) 
were recently described [125]. This nanosystem shows 
the potential for treatment of doxorubicin-resistant 
MCF-7 breast cancer cells and MCF-7/Adr xenografts 
in nude mice due to caspase-dependent mechanisms 
involving the activation of Bax (Bcl-2-associated X pro-
tein) and Bid (Bax-like BH3 protein) and inhibition 
of Bcl-2 protein. The sixfold increase of DOX intracel-
lular uptake and decreased drug efflux for functional 
nanocarriers when compare to the free compounds, 
Table 4 Examples of stimuli‑responsive nanotherapeutics
Multifunctional “smart” nanoparticles carrying drugs targeted preferentially to the cancer cells will lead to development of better treatment for patients with cancer
Stimulus factor Nanoformulation Active compound Tested cancer cell lines Reference
AMF Iron oxide/gold nanoparticles DNA Human cervical HeLa cells [218]
GSH PEGylated, RGD-modified, and DSPEIs-
functionalized gold nanorods
shRNA Human glioblastoma U-87 MG-GFP 
cells
[219]
GSH mPEGylated PLA-conjugated micelles Curcumin Human cervical HeLa cells [220]
Light Bridged silsesquioxane nanoparticles Plasmid DNA Human cervical HeLa cells [221]
Light Micelles Cisplatin prodrug and cyanine dye 
(Cypate)
Cisplatin-resistant lung cancer A549 
cells
[222]
Light/pH Chitosan derivative-coated CNTs 
encapsulated in nanogel
Doxorubicin Human cervical HeLa cells [223]
pH mPEGylated PLGA-P-Glutamic acid 
nanoparticles
Doxorubicin Lung cancer NCI-H460 cells, breast 
cancer MCF-7 cells
[224]
pH Multifunctional amphiphilic block 
copolymer containing cyclic orthoe-
ster and galactose groups
Doxorubicin Liver hepatocellular carcinoma HepG2 
cells
[225]
pH Porous bowl-like PLA-modified MSNs Doxorubicin Gastric cancer HGC-27 cells [226]
pH/GSH Multi-layered nanocomplexes Doxorubicin, siRNA Human hepatocarcinoma QGY-7703 
cells
[227]
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was reported [125]. Mitochondrial-targeting liposomes 
were also efficient in the therapy of paclitaxel-resistance 
lung cancer (A549/Taxol cell line) as demonstrated by 
Jiang et  al. Encapsulation of paclitaxel into pH-trig-
gered nanosystem resulted in caspase-dependent apop-
tosis of drug-resistant cancer cells and inhibition of 
growth of xenografted lung tumors due to facilitated 
cellular uptake and increased drug accumulation [126]. 
Enhanced effective drug concentration enables also the 
drug resistance in DOX-resistant breast cancer cells 
without the increased systemic toxicity [127]. Addi-
tionally, it was confirmed that nanoparticles-mediated 
delivery of paclitaxel into resistant P-gp-overexpressing 
cancer cells (KB-8-5) minimize its resistant phenotype, 
which is accomplished with enhanced cellular accumula-
tion and retention of drug. Prolonged retention within 
tumor tissues was also confirmed in xenografted cancer 
model, which was linked with higher degree of microtu-
bule stabilization, mitotic arrest, antiangiogenic activity, 
and inhibition of cell proliferation [128].
Silencing of drug resistance genes
The employment of siRNAs leading to cleavage and deg-
radation of target mRNA is a very promising approach 
in anti-cancer therapy. MDR1 encoding P-glycoprotein 
(P-gp), is one of the major targeted gene in the treat-
ment of drug-resistance cancers [129]. It is gener-
ally established, that silencing of MDR1 gene followed 
by decrease biosynthesis of P-gp results in increased 
tumors sensitivity [130]. Proper delivery of siRNAs by 
lipid-based nanoparticles or encapsulation of siRNA 
into PEGylated nanoliposomes, both lead to down-
regulation of P-gp expression in doxorubicin-resistant 
breast cancer MCF-7 cells [89]. Accordingly, employ-
ment of siRNA-based nanoformulation possess the 
potential to treat resistant tumors [131]. Interestingly, 
empty nanocarriers significantly increase the expression 
of P-gp.
Mac2 gene encoding mitotic arrest deficiency protein 2 
(Mac2) represents another target gene for siRNA-based 
interventions. Mac2 expression correlates with resist-
ance of cancer cells to a variety of antineoplastic agents, 
including paclitaxel and cisplatin [132, 133]. Interest-
ingly, complete silence of gene lead to chromosome 
missegregation-modulated cells death [134]. Consider-
ing these reports Nascimento et al. used EGFR-targeted 
chitosan nanoparticles to transport Mac2-aimed siRNA. 
They demonstrated that siRNA-based nanoformulation 
efficiently knock-down Mac2 gene causing apoptosis of 
non-small cells lung cancer cells, which is additionally 
improved by controlled delivery of siRNA using EGFR-
targeted homing ligand [135].
Inhibition of MDR‑associated proteins and efflux pumps
Decreasing activity of MDR-proteins and transporters 
responsible for efflux of cytotoxic drugs from cancer cells 
represents a major goal on the ways to deal with multid-
rug resistance in malignant tumors. It was proved, that 
the employment of Poloxamer 235 as inhibitor of P-gp 
pump results in increased permeability of various P-gp 
dependent drugs in resistant tumors due to its strong 
pore-forming properties [136]. Conducted studies con-
firmed that Poloxamers possess the ability to sensitize 
MDR cancer cells to various anti-cancer agents via incor-
poration into biological membrane and subsequent influ-
ence on intracellular functions, including mitochondrial 
respiration and synthesis of ATP, which is essential for 
the proper activity of ABC-dependent efflux transport 
proteins [137]. Tang and co-workers demonstrated that 
docetaxel-loaded PLGA–TPGS/Poloxamer 235 nanopar-
ticles possess great potential to be used as novel agent to 
treat drug-resistant breast cancer, since its use results in 
greater incorporation of docetaxel in MDR cancer cells, 
than both docetaxel and PLGA-TPGS nanoparticles 
alone [4]. It is also effective to use well-characterized first 
and third generation of P-gp inhibitors, verapamil and 
elacridar, to decrease the activity of efflux transporters. 
Singh et  al. reported that treatment with nanoformula-
tion containing doxorubicin-loaded cationic surfactant-
based nanoparticles with P-gp inhibitor encapsulated 
within it results in sensitization of DOX-resistant ovar-
ian cancer cells, which was determined by interaction of 
positively charged nanoparticles with negatively charged 
cell cancer surface and simultaneous caveolae-dependent 
endocytosis of nanosystem [138]. Moreover, Xu et  al. 
demonstrated promising results obtained during treat-
ment of drug-resistant A549 lung cancer cell with PLGA-
based nanoparticles loaded with cyclosporin A and 
encapsulated P-gp inhibitor [139]. These observations are 
in great agreement with reports demonstrated in previ-
ous years [140, 141].
The employment of nanoformulations to modulate 
pharmacokinetic properties of cytotoxic drugs
A number of studies report that nanotechnology provide 
an effective way to improve pharmacokinetic param-
eters of cytotoxic therapeutics employed in the systemic 
chemotherapy of malignancies. Application of nanotech-
nology provides the opportunity to influence cytotoxic 
drug low solubility in water, hydrophobic properties, the 
short half-life and rapid clearance. Oil in water (O/W) 
nanoemulsions, offer the improvement of chemical, 
enzymatic and colloidal stability of carried hydrophobic 
therapeutics [142]. In 2014 core-matched nanoemulsions 
(NEs) designed to co-deliver drugs of various chemical 
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nature was demonstrated. Functionalization of NE with 
vitamin E and TPGS facilitated delivery of both hydro-
phobic (paclitaxel) and hydrophilic (5-fluorouracil) drugs 
and synergism to overcome paclitaxel resistance in MDR 
human epidermal carcinoma cell line KB-8-5 and mouse 
xenograft model [63, 142]. Conducted studies confirmed 
that drugs encapsulation into nanoemulsion results in 
good stability, longer drugs circulation in blood, lower 
clearance and metabolism followed by higher accumu-
lation in cancer tissues [63]. Deol et  al. engaged FDA-
approved, low toxic and non-immunogenic dendrimers 
to design water-soluble dendron–conjugated gold nano-
particles (Den-AuNPs) in order to improve stability of 
AuNPs in water solutions [143]. Despite having the sig-
nificant anti-cancer potential, the medical use of gold-
based nanotherapeutics is expressively reduced due to 
poor biocompatibility of these structures determined 
by low colloidal stability required for the prevention of 
AuNPs agglomeration under physiological conditions 
[144]. As expected, the functionalization of gold-coated 
nanoparticles with dendrons prevent aggregation in bio-
logical fluids in broad spectrum of pH, in contrast to 
non-functionalized AuNPs irreversibly aggregated in 
acidic pH. Additionally, the presence of large dendron 
ligands protect nanoparticles core from the ionic disrup-
tions resulting in their good stability and solubility in 
the aqueous solution with the salt concentration of up 
to 100  mM [143]. There is also urgent need to improve 
biodistribution of paclitaxel, whose great antineoplastic 
properties are limited due to its insolubility in aqueous 
media and acquired cells chemoresistance. To solve this 
issue, paclitaxel was formulated at high concentration 
in Cremophor EL (Taxol®). However, with respect to its 
special features necessary to solubilize paclitaxel, cre-
mophor EL-based formulation cause a variety of adverse 
side effects, including allergic reactions, nephrotoxicity 
and precipitation in aqueous solution [145]. In order to 
achieve sufficient drug water-solubility, without concur-
rent side effects, several nanotechnology-based strate-
gies, including micellization, employment of liposomes 
and non-liposomal nanoparticles have been investigated 
[25, 26, 146]. Innovative approach to improve water-
solubility of paclitaxel lead to synthesis of nanoparticle 
conjugates formulated by covalent attachment of drug to 
gold nanoparticles via DNA linkers presented in 2011 by 
Zhang et al. The solubility of paclitaxel in aqueous buffer 
increased over 50-fold when compared to unconjugated 
drug. Additionally, fluorophore-based labeling of DNA 
linkers allows for visualization of conjugates within the 
cells [147].
Rapid development of nanotechnology provides possi-
bility to improve biodistribution and in vivo effectiveness 
of DNA-conjugated nanoparticles designed as controlled 
gene delivery systems characterized by low toxicity, good 
biocompatibility, biological activity and ability to enter 
cancer cells via scavenger receptor-mediated endocytosis 
[148]. Nevertheless, significant limitation using these sys-
tems in anti-cancer therapy is non-specific interaction of 
DNA-conjugated nanostructures with plasma proteins, 
resulting in nuclease-mediated rapid clearance [149]. 
Recently, it was reported that terminal PEGylation of the 
complementary DNA strand in DNA/AuNPs conjugates 
offers the approach to overcome adsorption to serum pro-
teins and determine the resistance of nanosystem against 
DNase I-based enzymatic digestion without the affecting 
of cellular uptake of loaded drugs [150]. Apart from this 
reports, Yang et  al. proved that engagement of isolated 
exosomes, a class of membrane secreted lipid vesicles 
that carry proteins and RNA among the cells, possess the 
great potential to delivery drugs across the blood–brain 
barrier and into brain via receptor-mediated endocytosis 
[151, 152]. To date, exosomes isolated from cell lines were 
employed mainly as nanocarriers to transport siRNA into 
cancerous cells and to deliver curcumin into target tumor 
tissues [153]. Studies performed on human glioblastoma-
astrocytoma U-87 MG cells confirmed that loading of 
exosomes with doxorubicin and paclitaxel allows the drugs 
transport through blood–brain barrier, in contrast to non-
functionalized drugs, that do not show brain uptake at 
all. Exosome-induced brain delivery was confirmed using 
zebrafish (Danio rerio) xenograft model. Still, there is 
urgent need for further studies that will evaluate the bio-
compatibility and effectiveness of these novel nanothera-
peutics [152]. Additionally, in  vivo studies performed by 
our research team confirmed that functionalization of 
RGD peptide (involved with the binding of proteins to 
cell surfaces) on the surface of MNPs considerably alters 
kinetic parameters of peptide and changes the way of drug 
excretion from the body of the mouse (Fig. 3).
Physical approaches based on nanoparticles 
as adjuvants in anti‑cancer therapy
Magnetic fluid hyperthermia (MFH)
Theranostic potential of nanomaterials assure employ-
ment of nanostructures in a wide range of medical 
application, including drug delivery systems, disease 
imaging and therapy. A number of studies confirmed 
that a defined subgroup of nanoparticles, mainly super-
paramagnetic nanoparticles (MNPs), due to their ability 
to release heat in the presence of alternating magnetic 
field might be used in cancer therapy. It was demon-
strated, that MNP-induced hyperthermic conditions 
(40–43  °C) leading to enhanced cancer cell death in the 
process of so-called MFH sensitize tumors to radio- and 
chemotherapy and might serve as adjuvant anti-cancer 
agent or as multifunctional nanosystems component to 
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administer together with other cancer treatment modali-
ties [154]. Magnetic nanoparticles have been tested in 
clinical trials as thermoablation method treatment of 
prostate cancer [155]. Numerous factors are involved 
in the process of hyperthermia-mediated cell death and 
the mechanism of MFH-induced killing of tumors is 
still under investigation. According to the latest studies 
changes in cell membrane fluidity resulting in greater 
permeability and susceptibility to antineoplastic agents, 
thermal degradation of BRCA2 (breast cancer suscep-
tibility protein 2), involved in repair of damaged DNA 
and increase in the amount of aggregated proteins and 
microtubule disruption-mediated proteotoxic stress play 
a major role in successful eradication of cancer cell using 
this method [156–159]. Previously, it was reported that 
MFH-induced decrease in the viability of melanoma and 
non-melanoma skin cancer cells results from necrosis 
and endoplasmic reticulum-mediated apoptosis, since 
activation of caspase 3/7, but no caspase 8 or 9 has been 
observed [160]. Current hyperthermia treatments are 
limited when tumors are described as deep-seated and 
by the risk of damage of health organ surrounding tumor 
tissues. In contrast, an oxygen-independent mechanism 
of MFH-mediated killing is based mainly on protein deg-
radation and dysfunction of cells membranes [161, 162].
Recently, Kossatz et al. synthetized magnetic nanopar-
ticles multifunctionalized with N6L, Nucant multivalent 
pseudopeptide targeting a nucleolin-receptor complex 
overexpressed at the cancer cell surface, and DOX for 
combined therapy linking MFH and anti-cancer drug 
delivery. Use of tumor-specific N6L and DOX on the 
MNPs surface to increase intracellular uptake help to 
achieve both hyperthermia- and DOX-induced cytotox-
icity [163]. The combined therapy using hyperthermia 
induced by gold nanorods and cisplatin-mediated chem-
otherapy against SKOV3 ovarian cancer cells gave also 
the promising results [164]. Synergistic effect between 
MFH and cisplatin-induced apoptosis against non-small 
cell lung cancer cells was described as well. CREKA-
based nanoplatform to deliver cisplatin into cancer cells 
was designed. It was shown that CREKA-conjugated iron 
oxide nanoparticles increased the cisplatin-mediated 
cytotoxicity due to hyperthermic conditions [67].
Photodynamic (PDT) and phototermal therapy (PTT)
Improvement of PDT selectivity and efficiency, due to 
employment of magnetic nanoparticles and other nano-
materials, was for a long time a main goal for scientists 
engaged in anti-cancer therapy. Photodynamic therapy, 
based on the selective photosensitizer internalization 
Fig. 3 Magnetic nanoparticles (MNPs) functionalization by homing molecules (RGD-peptide) increases particles elimination and prevents non-
specific accumulation in mice healthy organs. Pharmacokinetic of aminosilane coated magnetic nanoparticles (MNP@NH2) and their derivatives 
functionalized by RGD peptide (MNP@RGD) 8 h after intravenous injection (a). Structure of magnetic nanoparticles functionalized by RGD peptide 
and fluorescent probe DYE 800 CW (b). Biodistribution of MNP@NH2 and MNP@RGD 8 h after intravenous injection (c)
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into cancer cells in order to eliminate tumor tissue using 
specific wavelength irradiation seems one of the most 
interesting anti-cancer strategies in recent years. Photo-
sensiters-induced cell death occurs as the result of apop-
tosis, autophagy and necrosis process. However different 
factors are involved in PDT-mediated cancer cells killing. 
The list includes reactive oxygen species (ROS) and sin-
glet oxygen (1O2) generation, Bax activation and caspase-
dependent internucleosomal DNA cleavage followed by 
tumor-vasculature damage and activation of anti-cancer 
immune response [165]. In effect, nanoparticles acting as 
energy converters, transporters, and selective nanocar-
riers for photosensitizers, possess the great potential for 
use in synergistic antineoplastic therapy or as independ-
ent PDT components against skin, head and neck, cervi-
cal, bladder, prostate, brain and lung cancers [166–172].
Photothermal therapy represents an extension of PDT, 
where NIR-light is used to induce heat and rise of local 
temperature within tumor tissues leading to photoabla-
tion of the cells and cell death in oxygen-independent 
mechanism. Importantly, PTT allows the use of longer 
wavelength light than PDT (650–900  nm), which is less 
damaging for normal tissues [173]. Among a number of 
nanomaterials tested for their use in photothermal ther-
apy, gold nanoparticles (AuNPs) took a special place. 
Comprehensive research on gold-based nanomaterials 
properties proved that flower-like and core–shell AuNPs 
due to localized surface plasmon resonance (LSPR) 
are great candidates for the employment in PTT [174]. 
According to the latest studies, targeted photothermal 
therapy using gold nanoparticles conjugated with anti-
Mucin 7 antibodies might be useful in adjuvant therapy 
of urothelial cancer [175]. The recruitment of antibodies 
directed against mucin 7, being a urinary marker in blad-
der cancers, confirming the specificity of nanosystem and 
decrease the damage of health tissues, when compared to 
simple heating procedures used in hyperthermia [176]. 
Promising results were reported by Trinidad et  al. They 
present gold nanoparticles as the multifunctional system 
allowing the combined photodynamic and photothermal 
therapy against head and neck cancer. Enhancement of 
efficacy of such treatment was obtained through employ-
ment of macrophages, possessing affinity to hypoxic and 
necrotic cells within neoplastic tissues, survived after 
PTT [177]. Another synergistic therapeutic option, using 
simultaneously PDT and PTT, was demonstrated by Fan 
et  al. in 2014. They used nanoplatform built from A9 
RNA aptamer modified with methylene blue attached 
to PEGylated iron core within gold shell nanoparticles. 
Specificity of A9 aptamer to prostate specific membrane 
antigen (PSMA) make possible to distinguish prostate 
cancer cells from normal tissues. Conducted studies con-
firmed that formation of 1O2 by methylene blue followed 
by heat generation by gold nanoparticles results in signif-
icant decrease of LNCap cancer viability [178]. Reports 
demonstrated by other authors established that com-
bined PDT/PTT therapy using various nanomaterials, 
including photostable micelles gives great hope for effec-
tive antineoplastic therapy [179].
Radiosensitization by high‑Z nanoparticles
Although the radiation is highly non-selective thera-
peutic method, it has become one of the most impor-
tant therapeutic alternatives for patients diagnosed with 
malignancies. In analogy to the chemotherapy, one of the 
greatest challenges is to deliver a lethal dose of radiation 
to tumor environment within tolerance of healthy tissues. 
It was confirmed, that nanoparticles composed of high 
atomic (Z) numbers due to direct interaction with ion-
izing radiation act as radiosensitizers and allow for the 
heightening of therapeutic efficacy without increasing 
damages to the nearby healthy tissues. It is proposed, that 
mechanism of such interaction involves the enhancement 
of the photoelectric and Compton effects followed by 
the subsequent emissions of secondary electrons [180]. 
The most studies nanomaterials, whose properties make 
available to intensify production of secondary electrons 
and ROS and in that manner enhance radiation therapy 
effects are AuNPs, lanthanide-based NPs, titanium oxide 
nanotubes and cadmium selenide quantum dots [181–
183]. Noteworthy, the unique properties of nanoparticles 
allows the use of additional advantages of nanomaterials 
without sacrificing their radiosensitizing properties. Le 
Duc et  al. proposed the employment as radiosensitizers 
gadolinium-based nanoparticles, since they possess high 
Z number and possess the potential to be used as con-
trast agents in MRI [184]. The additional advantage of the 
employment of AgNPs might be enhanced Raman scat-
tering and antimicrobial properties [185].
A significant disadvantage of using nanoparticles as 
components of radiation therapy is its high sensitivity 
to a number of physicochemical and pharmacological 
parameters, such as irradiation energy, nanoparticle size, 
their concentration and localization in tumor tissues. 
Oxygen concentration present in the tumor environment 
represents a significant limitation in the employment of 
nanoparticles in radiation therapy. In 2014, it was dem-
onstrated that radiosensitizing properties of gold nano-
particles are correlated with the level of oxygen and is 
lower under hypoxic than oxic conditions [186].
Nanoformulations in recent clinical trials
Unique properties of nanomaterials makes available to 
employ them as effective antineoplastic agents or as a 
compound of combined therapy, in order to improve 
therapeutic effectiveness of existing anti-cancer drugs. 
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However, despite considerable amounts of described 
nanotechnology-based formulations, only a limited 
number of them was introduced into clinical trials. 
Recently, the interest of the researchers has focused on 
the employment of already used, FDA-approved nan-
odrugs (Abraxane®, Doxil®, Genexol-PM®) as the adju-
vants in combinatory therapy of malignancies. To date, 
Abraxane®, e.g. paclitaxel albumin-stabilized nanoparti-
cle formulation (nab-paclitaxel) was approved for treat-
ment of metastatic breast cancer [187]. There is more 
than 160 ongoing clinical trials involving nab-paclitaxel 
in combinatory therapy with other anti-cancer agents 
and focused primarily on the treatment of breast, lung or 
digestive and endocrine system neoplasms (according to 
the data provided by U.S. National Institutes of Health) 
[155]. Although some of them were terminated due to 
lack of funding, frequent dose adjustments or difficul-
ties in determination of optimal dose, it was presented 
as well that nab–paclitaxel with other antineoplastic 
agents might provide the way to overcome drug resist-
ance of malignancies [188, 189]. Results of phase I study 
described by Tsurutani et al. revealed that nab-paclitaxel 
in combination with S-1 (tegafur  +  5-chloro-2.4-dihy-
drooxypyridine  +  oteracil potassium) may be promis-
ing therapy for patients diagnosed with HER2-negative 
breast cancer [190]. In opposition, combined treatment 
with nab-paclitaxel with tigatuzumab does not result in 
higher objective response rate and progression-free sur-
vival [191]. Similarly, liposomal doxorubicin (Doxil®), 
registered for treatment of HIV-related Kaposi sarcoma, 
metastatic breast and ovarian cancer, is tested currently 
against recurrent, platinum-sensitive ovarian, primary 
peritoneal, and fallopian tube cancer when combined 
with carboplatin, bevacizumab and veliparib and for 
newly-diagnosed multiple myeloma in combination with 
bortezomib [192, 193]. Results of clinical trials demon-
strated recently are briefly summarized in Table 5.
It is noteworthy that results obtained from toxicity 
studies are highly variable. Recently, acceptable safety 
profile was demonstrated for combined treatment of 
recurrent epithelial ovarian cancer with carboplatin/
liposomal doxorubicin with tocilizumab (i.e. an anti-IL-
6R monoclonal antibody) and for combination of liposo-
mal doxorubicin with irinotecan [194, 195]. The highly 
active combination of cyclophosphamide, bortezomib, 
pegylated liposomal doxorubicin, and dexamethasone 
(CVDD) was also well tolerated by patients with multi-
ple myeloma [196]. Notably, the enrollment of pegylated 
liposomal doxorubicin with cyclophosphamide followed 
by paclitaxel was safe even for patients prone to car-
diotoxicity as presented in results of phase II CAPRICE 
study [197]. Moreover, treatment of peritoneal malignan-
cies with nanoparticulate paclitaxel have not induced 
toxic effects with low peritoneal clearance of drug pre-
served at the same time [198]. In contrast to these 
reports, the investigation of safety of Genexol-PM® i.e. 
Cremorphor EL-free polymeric micelle nanoformulation 
of paclitaxel combined with gemcitabine in patients with 
non-small cell lung cancer revealed frequent hematologi-
cal toxic effects [199]. The safety profile of Myocet® (non-
pegylated liposomal doxorubicin approved for treatment 
EGFR2-positive metastatic breast cancer) in children 
with high-grade glioma need to be studied as well [200].
Limitations facing nanoparticles‑based anti‑cancer 
therapies
It is undeniable that nanotechnology provides a variety of 
novel therapeutic options applicable in the treatment of 
solid tumor and hematological malignancies. However, 
this enthusiasm must be suppressed due to numerous 
reports on the considerable limitations facing nanotech-
nology-based anti-cancer therapies. First of all, phys-
icochemical properties of tested nanomaterials (i.e. its 
size, surface properties, zeta potential) influences greatly 
the stability in physiological fluids, their polydispersity, 
binding to blood proteins and associated efficiency of 
designed nanoformulation [14, 15]. However, the tumor 
accumulation and pharmacokinetics properties are not 
so easily to predict, even when the same polymers and 
elements of nanosystem are used. Similarly, they are no 
strong tendencies, when nanoformulations consist of 
particles with resembling size and shape are compared 
[201]. Overall, there is urgent need to recognize the exact 
properties of nanoparticles, which permit for maximum 
uptake and accumulation of drug in the target tissues.
Importantly, the unique properties of nanomaterials do 
not only condition their employment in therapy of can-
cers, but are also responsible for a variety of toxic effects. 
Despite the fact, that immobilization of anti-cancer 
agents on the surface of nanomaterials should improve 
their biocompatibility, it is confirmed that some nanopar-
ticles can cause toxic effects in healthy cells [75]. It was 
presented that SPIONs are potentially involved in cellular 
toxicity (generation of ROS, impairment of mitochon-
drial function, inflammation and formation of apoptotic 
bodies), alternations in gene expression and iron homeo-
stasis and disturbances of cell cycle regulation [202]. In 
2005, it was reported that intratracheal administration of 
multi-wall carbon nanotubes resulted in dose-dependent 
increase in inflammatory factors and fibrotic reactions, 
followed by the accumulation of CNT agglomerates in 
the airways [203]. Systemic immunosuppression after 
14-day exposure to inhaled multi-wall carbon nanotubes 
was reported by Mitchell et al. [204]. This confirms that 
comprehensive and detailed analysis of physicochemi-
cal properties and safety profiles of nanomaterials must 
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be performed before their introduction to further studies 
and clinical applications [204].
Apart from this, heterogeneity of cancer tumors and 
the development of MDR phenotypes represent a final 
challenge to effective antineoplastic strategy, since the 
cancer cells within tumor differ from their xenografts 
counterparts. Importantly, many physiological barriers, 
both extra- and intracellular reduces the total quantity 
of nanoparticles accumulated in the tumor. Additionally, 
despite the great potential of nanomaterials to treat solid 
tumors, the treatment of metastatic cancers is still chal-
lenging, since metastasized cells are too small to create 
microenvironment and EPR effect is less important [205].
It is established as well, that lack of standardization of 
preclinical research is recognized as considerable limi-
tation in design formulations applicable in the clinical 
settings. A comprehensive analysis of available data con-
firmed that a number of factors, including the choice of 
xenograft cell line, range of used experimental controls, 
inconsistent pharmacokinetic data, size of tested nano-
system and its dose, variation in tumor characteristics e.g. 
size and vascularization influences the proper assessment 
of delivery systems’ efficiency [201]. In order to solve this 
problem it is proposed that pre-clinical trials should be 
performed on standardized xenograft model, since differ-
ences in physiology results in alternations in circulation 
and drug accumulation, and tumor biology [206]. Dawid-
czyk et  al. recommended standardization of pre-clinical 
studies, including the introduction of standard cell line in 
xenografts model, reporting tumor accumulation as % ID 
(the percentage of administrated nanoparticles) and per-
forming the studies using tumor with specific type, size 
and unification of detection methods [201].
Conclusions
The rapid advance in nanotechnology provides different 
tools to develop new anti-cancer strategies. Employment 
of nanotechnology-based therapeutics should in near 
future overcome limitation of cancer surgery, radiation 
and chemotherapy. Nanomaterials possess the poten-
tial to be used as effective and selective antineoplastic 
agents for multidrug resistant cancers. Although many 
of designed nanoformulations have not led to clinical 
success after their introduction into clinical trials, sev-
eral of them provide hope for new therapeutic option in 
the treatment of malignancies. Current methods for the 
synthesis and analysis of nanosystems’ physicochemi-
cal and biological properties allows for comprehensive 
examination of their mechanism of action, as well as their 
effect on the living organism. Nevertheless, a significant 
diversity of nanomaterials, their specific physicochemical 
properties and a variety of effects on cellular processes, 
results in unexpected interactions and toxicity in in vivo 
settings. Despite this, it is expected that growing inter-
est in nanotechnology-based anti-cancer approaches will 
result in solutions that will soon be used as a part of mod-
ern, efficient and individualized antineoplastic therapy.
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